CompletedPhase 1NCT02870634

Phase 1 Dose Escalation and PK Study of Cu(II)ATSM in ALS/MND

Studying Amyotrophic lateral sclerosis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Collaborative Medicinal Development Pty Limited
Principal Investigator
Dominic Rowe, MD
Macquarie University
Intervention
Cu(II)ATSM(drug)
Enrollment
50 enrolled
Eligibility
18-75 years · All sexes
Timeline
20162020

Study locations (2)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02870634 on ClinicalTrials.gov

Other trials for Amyotrophic lateral sclerosis

Additional recruiting or active studies for the same condition.

See all trials for Amyotrophic lateral sclerosis

← Back to all trials